The handling of metastatic colorectal cancer

Annals of Oncology

Volumn 16, Issue SUPPL. 2, 2005, Pages

  Fornarini, G ^a   Guglielmi, A ^a   Sobrero, A ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ADVANCED CANCER; ALOPECIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG CHOICE; DRUG RESPONSE; DRUG WITHDRAWAL; HUMAN; LIVER METASTASIS; LONG TERM CARE; MONOTHERAPY; NEUROTOXICITY; PATIENT CARE; PRIORITY JOURNAL; SURVIVAL TIME;

EID: 21344466361     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi710     Document Type: Article

References (17)

1. Giacchetti S, Perpoint B, Zidani R et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-147.
2. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
3. Falcone G, Masi G, Allegrini G et al. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol 2002; 20: 4006-4014.
4. Roth A, Seium Y, Ruhstaller T et al. Oxaliplatin (Oxa) combined with irinotecan (CPT11) and 5FU/LV (OCFL) in metastatic colorectal cancer (MCRC): a phase I/II study. Proc Am Soc Clin Oncol 2002; 21: 570.
5. Adam R, Delvart V, Pascal G et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240: 644-657.
6. Scheithauer W, Rosen H, Kornek G et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993; 306: 752-755.
7. Cunningham D, Pyrhonen S, James RD et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-1418.
8. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047.
9. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
10. Grothey A, Deschler B, Kroening H et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusional/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2002; 21: 129 Abstr 512.
11. Grothey A, Sargent D, Goldberg RM et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209-1214.
12. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
13. Hurwitz H, Fehrenbacher L, Cartwright T et al. Bevacizumab prolongs survival in first-line colorectal patients: results of a phase III trial of bevacizumab in combination with bolus IFL as first line therapy in subjects with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2003; 22: 253 Abstr 1013.
14. Colucci G, Maiello E, Gebbia V et al. Preliminary results of a randomized multicenter trial of the Gruppo Oncologico Italia Meridionale (GOIM) comparing FOLFIRI vs FOLFOX in advanced colorectal cancer. Proc Am Soc Clin Oncol 2003; 22: 255 Abstr 1021.
15. Grothey A, Jordan K, Kellner O et al. Randomized phase II trial of capecitabine plus irinotecan (Capiri) vs capecitabine plus oxaliplatin (CapOx) as first-line therapy of advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2003; 22: 255 Abstr 1022.
16. Maughan TS, James RD, Kerr DJ et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet 2003; 361: 457-464.
17. Lal R, Dickson J, Cunningham D et al. A randomised trial comparing defined-duration with continuous irinitecan until disease progression in fluoropirimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer. J Clin Oncol 2004; 22: 3023-3031.